Novartis announced plans to build a fourth US radioligand therapy manufacturing facility in Winter Park, Florida, as part of ...

Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.

The START Center for Cancer Research dosed the first U.S. patient in Moderna’s Phase 1 trial of mRNA-4106, a multivalent mRNA-based cancer vaccine targeting advanced solid tumors. The study evaluates ...

GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...

Deloitte's inaugural survey reveals high expectations for Generative AI among organizations, with 79% of respondents expecting it to transform their organizations within three years. However, the ...

Roche has announced that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Elecsys pTau217 blood test for the diagnosis of Alzheimer’s disease. This ...

The FDA has approved Illumina's TruSight Oncology Comprehensive test as a companion diagnostic for two cancer indications. This biomarker test profiles over 500 genes in solid tumors, aiding in the ...

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...

An international PANORAMA study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on routine CT scans. Across 3,440 patients, AI achieved an AUROC of 0 ...

Zymeworks Inc. announced that the United States Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ZW171. This novel bispecific antibody targets ...

Rznomics has received FDA Orphan Drug Designation for RZ-001, a novel RNA-based therapy for Hepatocellular carcinoma. RZ-001 employs advanced RNA editing to target and suppress cancer growth, showing ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical for advanced hepatocellular carcinoma. The therapy uses a GPC3-targeting ...